Sovran Advisors, LLC Galectin Therapeutics Inc Transaction History
Sovran Advisors, LLC
- $954 Billion
- Q2 2025
A detailed history of Sovran Advisors, LLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Sovran Advisors, LLC holds 188,972 shares of GALT stock, worth $544,239. This represents 0.04% of its overall portfolio holdings.
Number of Shares
188,972
Previous 199,830
5.43%
Holding current value
$544,239
Previous $276 Million
43.22%
% of portfolio
0.04%
Previous 0.04%
Shares
3 transactions
Others Institutions Holding GALT
# of Institutions
101Shares Held
9.89MCall Options Held
587KPut Options Held
2.02M-
Vanguard Group Inc Valley Forge, PA2.19MShares$6.31 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$4.5 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.22MShares$3.52 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA853KShares$2.46 Million0.0% of portfolio
-
Geneos Wealth Management Inc.423KShares$1.22 Million0.02% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $171M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...